Drug Profile
JZP 150
Alternative Names: JZP-150; PF-04457845; PF-4457845; PF-’845Latest Information Update: 26 Dec 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Jazz Pharmaceuticals plc; Pfizer; Stockholm Centre for Dependency Disorders
- Class Analgesics; Anxiolytics; Benzylidene compounds; Piperidines; Pyridazines; Small molecules
- Mechanism of Action Fatty acid amide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alcoholism; Pain; Post-traumatic stress disorders
Most Recent Events
- 21 Dec 2023 Discontinued - Phase-II for Post-traumatic stress disorders (In adults) in USA (PO)
- 21 Dec 2023 Discontinued - Preclinical for Post-traumatic stress disorders in Ireland (PO)
- 21 Dec 2023 Topline adverse events and efficacy data from a phase-II trial in Post-traumatic stress disorders released by Jazz Pharmaceuticals